Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)

The Invesco KBW Bank ETF tracks a sector-specific index of leading U.S. banking firms, emphasizing large and regional institutions.

Teva (TEVA) Q3 2025 Earnings Call Transcript

As of January 28, 2026, Corcept Therapeutics (NASDAQ: CORT) stands at a critical crossroads that perfectly encapsulates the high-stakes nature of the biotechnology sector. Once a niche player focused solely on the rare endocrine disorder Cushing’s syndrome, Corcept has evolved into a diversified clinical-stage powerhouse. While the company recently weathered a significant regulatory storm involving [...]

NEW BRUNSWICK, N.J. — Johnson & Johnson (NYSE: JNJ) has officially closed the chapter on a year many analysts described as "transitional," reporting full-year 2025 earnings that met expectations while setting a bold trajectory for the year ahead. In its January 21, 2026, earnings call, the healthcare titan revealed it is

As the opening bell approaches on January 21, 2026, all eyes on Wall Street are fixed on Johnson & Johnson (NYSE: JNJ), which is set to report its fourth-quarter and full-year 2025 financial results. This report serves as a critical barometer for the healthcare giant’s first full year as a

Date: January 14, 2026 Viatris Inc. (NASDAQ: VTRS) stands at a critical crossroads in early 2026. After years of functioning as a complex, debt-laden conglomerate formed from the massive merger of Mylan and Pfizer’s Upjohn division, the company has emerged from its "Phase 1" stabilization period. Today, Viatris is no longer just a "generic drug [...]

Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair Story

Duquesne Family Office's billionaire boss has jettisoned the faces of the artificial intelligence (AI) revolution in favor of a drugmaker whose shares have rallied 191% since the beginning of 2024.

This combination of growth and value stocks has the tools and intangibles necessary to outperform in the year to come.

Teva Pharmaceutical is more complex than you may realize, even though that's part of the company's plan.

Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.

Glenview Capital Management reduced its stake in Alight by roughly 16% during the third quarter.

Glenview Capital Management added to its massive position in Teva Pharmaceuticals stock.

The global prescription drugs market is on the cusp of a significant expansion, with recent market reviews and forecasts projecting a robust growth trajectory through 2035. This anticipated surge, driven by an aging global population, the rising prevalence of chronic diseases, and relentless innovation in pharmaceutical research and development, signals

Stanley Druckenmiller is considered one of the greatest investors of all time.

Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.

JPMorgan said the implied net impact aligns with recent commentary from Novo Nordisk, Teva and AbbVie during earnings season.

Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA.

Jury convicts Done Global founder Ruthia He and former top doctor David Brody in a federal case alleging illegal Adderall distribution through the telehealth platform.

Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation.

Duquesne Family Office's billionaire boss has gone full contrarian by selling Wall Street's two artificial intelligence (AI) darlings and piling into a previously struggling pharmaceutical stock.